Efficacy and Safety of Paclitaxel and Cisplatin in the Treatment of Advanced Ovarian Cancer by Different Means of Administration
Abstract
In the treatment of advanced ovarian cancer, paclitaxel and cisplatin are administered in different ways. This paper discusses the efficacy and safety of this approach. Methods: Data were searched through literature, and classified discussion was conducted on this basis. The experimental group and the control group were treated in different ways, and the analysis was carried out by way of comparison, so as to explore the therapeutic effect of drug administration route on advanced ovarian cancer patients. Results: After the completion of the statistical survey, the experimental group was compared with the control group by intravenous infusion after using the new administration method. In terms of the results, the intraperitoneal infusion method had a better effect on the treatment of patients. In terms of the data, this method could effectively improve the long-term survival rate of patients. However, in terms of hepatorenal and peripheral neurotoxicity, intraperitoneal perfusion was more toxic. In terms of musculoarthralgia, the type of intraperitoneal perfusion, has a much greater effect on the patient. Conclusions: Intraperitoneal perfusion has positive therapeutic effects in patients with advanced ovarian cancer, but it is more burdsome to the body. Therefore, in the process of use, we should make comprehensive selection according to the specific situation of patients.References
Hu J, Xing J, Chen J, et al. Meta-analysis of the efficacy of paclitaxel combined with cisplatin in the treatment of advanced ovarian cancer by intraperitoneal infusion versus intravenous administration alone (in Chinese). Journal of North China University of Science and Technology (Health Sciences Edition) 2020; 22(02): 119–129.
Du C. Efficacy and safety evaluation of carboplatin combined with paclitaxel in patients with advanced ovarian cancer and pharmacokinetic study of carboplatin (in Chinese) [Master’s thesis]. Tianjin Medical University; 2012.
Mu W. Dose exploration and efficacy analysis of carboplatin intraperitoneal infusion chemotherapy for advanced ovarian cancer (in Chinese) [Master’s thesis]. Air Force Medical University of PLA (the Fourth Military Medical University); 2018.
Chen X, Feng X. Comparison of efficacy of paclitaxel and nedaplatin combined chemotherapy regimens in the treatment of advanced ovarian cancer (in Chinese). Henan Medical Research 2015; 24(04): 27–28.
Chen Y, Xie R, Liang Y. Clinical effect of paclitaxel combined with cisplatin in the treatment of advanced ovarian cancer and its effect on immune system (in Chinese). Practical Journal of Clinical Medicine 2015; 12(04): 134–137.
Wu G, Liu L. Efficacy and adverse reactions of different cisplatin methods combined paclitaxel intravenous drip in advanced ovarian cancer. Chinese Journal of Clinical Oncology and Rehabilitation 2016; 23(03): 300–302.
Hou F. Clinical efficacy and survival rate of neoadjuvant chemotherapy for advanced epithelial ovarian cancer (in Chinese) [Master’s thesis]. Lanzhou University; 2020.
Zhang Q. Clinical effect of carboplatin combined with paclitaxel in the treatment of advanced epithelial ovarian cancer (in Chinese) [Master’s thesis]. Anhui Medical University; 2019.
Wang Z. Comparison of efficacy of different administration methods of paclitaxel combined with nedaplatin in the treatment of advanced ovarian cancer (in Chinese).Shenzhen Journal of Integrated Traditional Chinese and Western Medicine 2019; 29(18): 157–158.
Wang L. Efficacy of different administration of paclitaxel combined with nedaplatin in the treatment of advanced ovarian cancer (in Chinese).China Continuing Medical Education 2018; 10(18): 111–112.
Copyright (c) 2021 Datian Fu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
